Emerging Pro-drug and Nano-drug Strategies for Gemcitabine-based Cancer Therapy

Overview

Journal Asian J Pharm Sci

Date 2022 Mar 9

PMID 35261643

Authors

Haijie Han

Su Li

Yueyang Zhong

Yue Huang

Kai Wang

Qiao Jin

Jian Ji

Ke Yao

Affiliations

Soon will be listed here.

Abstract

Gemcitabine has been extensively applied in treating various solid tumors. Nonetheless, the clinical performance of gemcitabine is severely restricted by its unsatisfactory pharmacokinetic parameters and easy deactivation mainly because of its rapid deamination, deficiencies in deoxycytidine kinase (DCK), and alterations in nucleoside transporter. On this account, repeated injections with a high concentration of gemcitabine are adopted, leading to severe systemic toxicity to healthy cells. Accordingly, it is highly crucial to fabricate efficient gemcitabine delivery systems to obtain improved therapeutic efficacy of gemcitabine. A large number of gemcitabine pro-drugs were synthesized by chemical modification of gemcitabine to improve its biostability and bioavailability. Besides, gemcitabine-loaded nano-drugs were prepared to improve the delivery efficiency. In this review article, we introduced different strategies for improving the therapeutic performance of gemcitabine by the fabrication of pro-drugs and nano-drugs. We hope this review will provide new insight into the rational design of gemcitabine-based delivery strategies for enhanced cancer therapy.

Citing Articles

An exploration of the ocular mysteries linking nanoparticles to the patho-therapeutic effects against keratitis.

Qu S, Zheng S, Muhammad S, Huang L, Guo B J Nanobiotechnology. 2025; 23(1):184.

PMID: 40050881 PMC: 11887204. DOI: 10.1186/s12951-025-03230-3.

Gemcitabine-Loaded Microbeads for Transarterial Chemoembolization of Rabbit Renal Tumor Monitored by F-FDG Positron Emission Tomography/X-Ray Computed Tomography Imaging.

Zhang X, Li T, Tong J, Zhou M, Wang Z, Liu X Pharmaceutics. 2025; 16(12.

PMID: 39771587 PMC: 11678015. DOI: 10.3390/pharmaceutics16121609.

Improved Antitumor Efficiency of -Tetradecyloxycarbonyl Gemcitabine-Loaded Liposomes for Pancreatic Cancer Chemotherapy.

Wang D, Wang X, Li Y, Wang X, Wang X, Su J Int J Nanomedicine. 2024; 19:13391-13410.

PMID: 39679246 PMC: 11646436. DOI: 10.2147/IJN.S485861.

Dual-Action Gemcitabine Delivery: Chitosan-Magnetite-Zeolite Capsules for Targeted Cancer Therapy and Antibacterial Defense.

Guarin-Gonzalez Y, Cabello-Guzman G, Reyes-Gasga J, Moreno-Navarro Y, Vergara-Gonzalez L, Martin-Martin A Gels. 2024; 10(10).

PMID: 39451325 PMC: 11507657. DOI: 10.3390/gels10100672.

Connecting dots between nucleotide biosynthesis and DNA lesion repair/bypass in cancer.

Lin J, Oludare A, Jung H Biosci Rep. 2024; 44(9).

PMID: 39189649 PMC: 11427732. DOI: 10.1042/BSR20231382.

References

Reddy L, Ferreira H, Dubernet C, Mouelhi S, Desmaele D, Rousseau B . Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms. Anticancer Drugs. 2008; 19(10):999-1006. DOI: 10.1097/CAD.0b013e3283126585. View

Dadfar S, Roemhild K, Drude N, von Stillfried S, Knuchel R, Kiessling F . Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019; 138:302-325. PMC: 7115878. DOI: 10.1016/j.addr.2019.01.005. View

Han H, Yin Q, Tang X, Yu X, Gao Q, Tang Y . Development of mucoadhesive cationic polypeptide micelles for sustained cabozantinib release and inhibition of corneal neovascularization. J Mater Chem B. 2020; 8(23):5143-5154. DOI: 10.1039/d0tb00874e. View

Zhou J, Yang Y, Zhang C . Toward Biocompatible Semiconductor Quantum Dots: From Biosynthesis and Bioconjugation to Biomedical Application. Chem Rev. 2015; 115(21):11669-717. DOI: 10.1021/acs.chemrev.5b00049. View

Khare V, Kour S, Alam N, Dubey R, Saneja A, Koul M . Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate. Int J Pharm. 2014; 470(1-2):51-62. DOI: 10.1016/j.ijpharm.2014.05.005. View

Mukherjee P . Targeted delivery using inorganic nanosystem. Preface. Adv Drug Deliv Rev. 2009; 62(3):283. DOI: 10.1016/j.addr.2009.11.001. View

Maiti S, Park N, Han J, Jeon H, Lee J, Bhuniya S . Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug. J Am Chem Soc. 2013; 135(11):4567-72. DOI: 10.1021/ja401350x. View

Brusa P, Immordino M, Rocco F, Cattel L . Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. Anticancer Res. 2007; 27(1A):195-9. View

Kim D, Im B, Hwang H, Na K . Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment. Biomaterials. 2018; 183:139-150. DOI: 10.1016/j.biomaterials.2018.08.052. View

10.

Wang Y, Yang X, Liu T, Li Z, Leskauskas D, Liu G . Molecular-Level Control over Plasmonic Properties in Silver Nanoparticle/Self-Assembling Peptide Hybrids. J Am Chem Soc. 2020; 142(20):9158-9162. PMC: 7657666. DOI: 10.1021/jacs.0c03672. View

11.

Poon C, He C, Liu D, Lu K, Lin W . Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. J Control Release. 2015; 201:90-9. PMC: 4624312. DOI: 10.1016/j.jconrel.2015.01.026. View

12.

Han H, Wang J, Chen T, Yin L, Jin Q, Ji J . Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment. J Colloid Interface Sci. 2017; 507:217-224. DOI: 10.1016/j.jcis.2017.07.047. View

13.

Zhu S, Wonganan P, Lansakara-P D, OMary H, Li Y, Cui Z . The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression. Biomaterials. 2012; 34(9):2327-39. PMC: 3552003. DOI: 10.1016/j.biomaterials.2012.11.053. View

14.

Meng H, Zhao Y, Dong J, Xue M, Lin Y, Ji Z . Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano. 2013; 7(11):10048-65. PMC: 3878438. DOI: 10.1021/nn404083m. View

15.

Meng H, Wang M, Liu H, Liu X, Situ A, Wu B . Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano. 2015; 9(4):3540-57. PMC: 4415452. DOI: 10.1021/acsnano.5b00510. View

16.

Wang H, Liu X, Wang Y, Chen Y, Jin Q, Ji J . Doxorubicin conjugated phospholipid prodrugs as smart nanomedicine platforms for cancer therapy. J Mater Chem B. 2020; 3(16):3297-3305. DOI: 10.1039/c4tb01984a. View

17.

Adema A, Smid K, Losekoot N, Honeywell R, Verheul H, Myhren F . Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest New Drugs. 2011; 30(5):1908-16. PMC: 3432794. DOI: 10.1007/s10637-011-9756-8. View

18.

Ghosh B, Biswas S . Polymeric micelles in cancer therapy: State of the art. J Control Release. 2021; 332:127-147. DOI: 10.1016/j.jconrel.2021.02.016. View

19.

Zhang H, Wang K, Na K, Li D, Li Z, Zhao D . Striking a Balance between Carbonate/Carbamate Linkage Bond- and Reduction-Sensitive Disulfide Bond-Bearing Linker for Tailored Controlled Release: In Situ Covalent-Albumin-Binding Gemcitabine Prodrugs Promote Bioavailability and Tumor Accumulation. J Med Chem. 2018; 61(11):4904-4917. DOI: 10.1021/acs.jmedchem.8b00293. View

20.

Wang J, Zhang X, Cen Y, Lin X, Wu Q . Antitumor gemcitabine conjugated micelles from amphiphilic comb-like random copolymers. Colloids Surf B Biointerfaces. 2016; 146:707-15. DOI: 10.1016/j.colsurfb.2016.07.027. View